RayKnowChina Research Map
Shortlist

Tianjin

Tianjin Chest Hospital

天津市胸科医院

Listed for 5 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Tianjin Chest Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Lung cancer肺癌39 papers led
  2. Coronary heart disease冠心病36 papers led2 open trials led
  3. Congenital heart disease先天性心脏病4 papers led
  4. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  5. Fabry disease法布雷病1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Pancreatic cancer, Breast cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Lung cancer

肺癌

Led 39 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
39
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
9
led by another institution
Papers led per year
2021: 7720212022: 5520222023: 6620232024: 5520242025: 16162025

7 hospitals in Tianjin for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07416474

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai

  2. Recruiting
    A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07586202

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin

  3. Recruiting
    A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06962865

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou

  4. Recruiting
    Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07154706

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Jinan, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Tianjin, Wuhan, Xi'an, Zhengzhou

  5. Recruiting
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07182682

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou

  6. Recruiting
    Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07185997

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou

  7. Recruiting
    A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05913089

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Fuzhou, Shanghai, Taiyuan, Tianjin, Weifang

  8. Not yet recruiting
    A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05990127

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou

  9. Enrolling by invitation
    Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
    Phase
    Phase 3
    Started
    2021-08
    Posted
    Registry
    NCT04762459

    Age 18 years to 130 years (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicineRadiation oncology

Over half of these papers are lab or animal studies.

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led39
  1. Enhanced pulmonary nodule detection with U-Net, YOLOv8, and swin transformer.2025BMC medical imagingFree full text
  2. Identifying diagnostic markers and establishing prognostic model for lung cancer based on lung cancer-derived exosomal genes.2025Cancer biomarkers : section A of Disease markersFree full text
  3. A radiomics-based machine learning model and SHAP for predicting spread through air spaces and its prognostic implications in stage I lung adenocarcinoma: a multicenter cohort study.2025Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  4. Spatial transcriptomic analysis across histological subtypes reveals molecular heterogeneity and prognostic markers in early-stage lung adenocarcinoma.2025Clinical and translational medicineFree full text
  5. Kaempferitrin Regulates the Proliferation, Metastasis, and Immune Escape of Nonsmall Cell Lung Cancer by Inhibiting the Akt/NF-κB Pathway.2025Drug development research
  6. Guanylate-binding proteins score and a CBFA2T3-included risk model define immune microenvironment and chemosensitivity in lung adenocarcinoma.2025European journal of medical researchFree full text
  7. Integrative modeling of malignant epithelial programs in EGFR-mutant LUAD via single-cell transcriptomics and multi-algorithm machine learning.2025Frontiers in immunologyFree full text
  8. Single-cell transcriptomic profiling reveals the heterogeneity of epithelial cells in lung adenocarcinoma lymph node metastasis and develops a prognostic signature.2025Frontiers in immunologyFree full text
  9. Development of a machine learning-derived dendritic cell signature for prognostic stratification in lung adenocarcinoma.2025Frontiers in immunologyFree full text
  10. Falcarindiol Suppresses Malignant Progression and Induces Ferroptosis in Non-Small Cell Lung Cancer by Regulating JAK/STAT3 Axis.2025Journal of biochemical and molecular toxicology
  11. Integrative single-cell and machine learning approach to characterize immunogenic cell death and tumor microenvironment in LUAD.2025Journal of translational medicineFree full text
  12. A Machine Learning-Derived Taurine Metabolism Signature Predicts Prognosis and Immune Landscape in Lung Adenocarcinoma via Integrative Single-Cell Analysis.2025Mediators of inflammationFree full text
  13. Sennoside A represses the malignant phenotype and tumor immune microenvironment of non-small cell lung cancer cells by inhibiting the TRAF6/NF-κB pathway.2025Naunyn-Schmiedeberg's archives of pharmacology
  14. A nicotinamide metabolism-related gene signature for predicting immunotherapy response and prognosis in lung adenocarcinoma patients.2025PeerJFree full text
  15. Druggable genome-wide Mendelian randomization integrating GWAS and eQTL/pQTL data identifies targets for lung squamous cell carcinoma.2025Scientific reportsFree full text
  16. Single-Cell and Spatial Transcriptomics-Based Research Reveals Association Between M2a Macrophages and Tumor Spread through Air Spaces in Lung Adenocarcinoma.2025The American journal of pathology
  17. Preoperative assessment of tertiary lymphoid structures in stage I lung adenocarcinoma using CT radiomics: a multicenter retrospective cohort study.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  18. Macrophage heterogeneity and oncogenic mechanisms in lung adenocarcinoma: insights from scRNA-seq analysis and predictive modeling.2024Frontiers in immunologyFree full text
  19. Integrative single-cell analysis of LUAD: elucidating immune cell dynamics and prognostic modeling based on exhausted CD8+ T cells.2024Frontiers in immunologyFree full text
  20. Sinensetin inhibits the movement ability and tumor immune microenvironment of non-small cell lung cancer through the inactivation of AKT/β-catenin axis.2024Journal of biochemical and molecular toxicology
  21. CRTAC1 identified as a promising diagnosis and prognostic biomarker in lung adenocarcinoma.2024Scientific reportsFree full text
  22. CircPIM3 regulates taxol resistance in non-small cell lung cancer via miR-338-3p/TNFAIP8 axis.2023Anti-cancer drugs
  23. A pretreatment prediction model of grade 3 tumors classed by the IASLC grading system in lung adenocarcinoma.2023BMC pulmonary medicineFree full text
  24. Screening of potential microbial markers for lung cancer using metagenomic sequencing.2023Cancer medicineFree full text
  25. Real-world surgical treatment patterns and clinical outcomes in patients with stages IA-IIIA non-small cell lung cancer: a retrospective multicentric observational study involving 11,958 patients.2023Journal of cancer research and clinical oncologyFree full text
  26. Mediastinal cavernous hemangioma with concurrent primary lung adenocarcinoma.2023Pulmonology
  27. SETD1A-mediated H3K4me3 methylation upregulates lncRNA HOXC-AS3 and the binding of HOXC-AS3 to EP300 and increases EP300 stability to suppress the ferroptosis of NSCLC cells.2023Thoracic cancerFree full text
  28. Impact of preoperative biopsy on tumor spread through air spaces in stage I non-small cell lung cancer: a propensity score-matched study.2022BMC pulmonary medicineFree full text
  29. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.2022Cancer control : journal of the Moffitt Cancer CenterFree full text
  30. Pretreatment prediction of tumour spread through air spaces in clinical stage I non-small-cell lung cancer.2022European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic SurgeryFree full text
  31. ZNF143 Expression is Associated with COPD and Tumor Microenvironment in Non-Small Cell Lung Cancer.2022International journal of chronic obstructive pulmonary diseaseFree full text
  32. Identification of Recurrent Insertions and Deletions in Exon 18 and 19 of Human Epidermal Growth Factor Receptor 2 as Potential Drivers in Non-Small-Cell Lung Cancer and Other Cancer Types.2022JCO precision oncologyFree full text
  33. Multi-line treatment with tyrosine kinase inhibitors enabled in 4-year survival for patient with stage IV lung adenocarcinoma: a case report.2021Annals of palliative medicine
  34. Investigation of differentially expressed gene profile for cisplatin-treated lung cancer patients.2021Anti-cancer drugs
  35. The risk and prognostic factors for brain metastases in esophageal cancer patients: an analysis of the SEER database.2021BMC cancerFree full text
  36. Perioperative outcomes of combined heart surgery and lung tumor resection: a systematic review and meta-analysis.2021Journal of cardiothoracic surgeryFree full text
  37. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.2021Journal of clinical laboratory analysisFree full text
  38. Glutathione S‑transferase ω 1 promotes the proliferation, migration and invasion, and inhibits the apoptosis of non‑small cell lung cancer cells, via the JAK/STAT3 signaling pathway.2021Molecular medicine reportsFree full text
  39. Elevated expression of ASF1B correlates with poor prognosis in human lung adenocarcinoma.2021Personalized medicine
Chinese-language papers (not in the count)1
  1. [Analysis of Influencing Factors of Complications for CT-guided 
Percutaneous Lung Biopsy].2024Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
All its trials on ClinicalTrials.gov, any status26
  1. Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPDStatus unknownNCT05578222Lead sponsorPhase 2Start 2022-10
  2. A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung CancerCompletedNCT03429192Lead sponsorStart 2017-12
  3. RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT07416474Study sitePhase 3Start 2026-04
  4. A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCRecruitingNCT07586202Study sitePhase 2Start 2026-07
  5. Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)RecruitingNCT07154706Study sitePhase 3Start 2025-08
  6. A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLCRecruitingNCT06962865Study sitePhase 2Start 2025-06
  7. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsRecruitingNCT07185997Study sitePhase 3Start 2025-12
  8. A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryRecruitingNCT07182682Study sitePhase 3Start 2025-12
  9. A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung CancerNot yet recruitingNCT05990127Study sitePhase 3Start 2023-11
  10. A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung CancerRecruitingNCT05913089Study sitePhase 2Start 2023-06
  11. Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour ResectionEnrolling by invitationNCT04762459Study sitePhase 3Start 2021-08
  12. Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT07162883Study sitePhase 3Start 2025-11
  13. Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)Active, not recruitingNCT06577792Study siteN/AStart 2023-08
  14. A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)Active, not recruitingNCT05722015Study sitePhase 3Start 2023-02
  15. Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.Status unknownNCT05922345Study sitePhase 3Start 2023-06
  16. Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative DeliriumCompletedNCT05273827Study siteStart 2022-03
  17. A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)Status unknownNCT04964479Study sitePhase 3Start 2021-08
  18. A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in ChinaCompletedNCT04830826Study siteStart 2020-07
  19. A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung CancerStatus unknownNCT04439890Study sitePhase 3Start 2019-08
  20. Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC PatientsCompletedNCT03613467Study siteStart 2018-07
  21. Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical ResectionTerminatedNCT03479294Study siteStart 2018-03
  22. A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung CancerCompletedNCT03451526Study siteStart 2017-12
  23. A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC PatientsCompletedNCT03429673Study siteStart 2017-12
  24. A Study to Explore Prognoses of NSCLC Patients Complicated With OligometastasesStatus unknownNCT03427541Study siteStart 2017-12
  25. A Study to Evaluate Clinical Characteristics of Lung Cancer in Patients With Surgeries and Adjuvant TherapiesCompletedNCT03421093Study siteStart 2017-12
  26. A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung CancerCompletedNCT03427567Study siteStart 2017-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 36 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.7%.

Papers led
36
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 7720212022: 9920222023: 8820232024: 9920242025: 332025

9 hospitals in Tianjin for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TTE Improves Clinical Management of Stable Chest Pain
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT07063147

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Chest HospitalTianjin

  2. Recruiting
    CCTA Improves Clinical Management of Stable Chest Pain
    Phase
    Not given
    Started
    2016-01
    Posted
    Registry
    NCT04691037

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Chest Hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  3. Recruiting
    Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
    Phase
    Phase 4
    Started
    2025-11
    Posted
    Registry
    NCT07110415

    Age 40 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Dalian, Daqing, Guangzhou, Guiyang, Hangzhou, Harbin, Huzhou, Jinan, Lanzhou, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Xi'an, Yantai, Yinchuan, Zhangjiakou, Zhuhai

  4. Not yet recruiting
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    Phase
    N/A
    Started
    2021-09
    Posted
    Registry
    NCT04995159

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led36
  1. Relationship between coronary artery calcification and plaque vulnerability, a qualitative and quantitative optical coherence tomography study.2025International journal of cardiology
  2. Electrocardiographic and clinical predictors for in-hospital mortality in patients with acute myocardial infarction caused by left main coronary artery occlusion.2025MedicineFree full text
  3. A sensing strategy based on novel pyrene-functionalized MOFs for sVCAM-1 detection and prognostic assessment in coronary heart disease.2025Talanta
  4. Interventional treatment of non-spontaneously healed spontaneous coronary artery dissection: a case report.2024BMC cardiovascular disordersFree full text
  5. The relative and combined ability of stress hyperglycemia ratio and N-terminal pro-B-type natriuretic peptide to predict all-cause mortality in diabetic patients with multivessel coronary artery disease.2024Cardiovascular diabetologyFree full text
  6. Triglyceride-glucose Index as a Valuable Marker to Predict Severity of Coronary Artery Disease: A Retrospective Cohort Study.2024Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisFree full text
  7. The Effect of Angiotensin Receptor Blockers on In-Stent Restenosis After Stent Implantation: A Meta-Analysis.2024Heart, lung & circulation
  8. Differential Expression of mRNA in Peripheral Blood Mononuclear Cells May Predict Postoperative Atrial Fibrillation in Coronary Artery Bypass Surgery Patients.2024Journal of cardiovascular translational researchFree full text
  9. Association of the PCSK6 rs1531817(C/A) polymorphism with the prognosis and coronary stenosis in premature myocardial infarction patients: a prospective cohort study.2024Lipids in health and diseaseFree full text
  10. Proprotein convertase subtilisin/kexin 9 inhibitor downregulates microRNA-130a-3p expression in hepatocytes to alleviates atherosclerosis progression.2024Naunyn-Schmiedeberg's archives of pharmacology
  11. Monocyte to high-density lipoprotein cholesterol ratio predicts restenosis of drug-eluting stents in patients with unstable angina pectoris.2024Scientific reportsFree full text
  12. Comparison of clinical effects of coronary artery bypass grafting between left anterior small thoracotomy approach and lower-end sternal splitting approach.2024The Journal of international medical researchFree full text
  13. Diagnostic Performance of Machine Learning-Derived Radiomics Signature of Pericoronary Adipose Tissue in Coronary Computed Tomography Angiography for Coronary Artery In-Stent Restenosis.2023Academic radiology
  14. Lipoprotein Subfractions as Markers for Predicting the Presence and Severity of Coronary Artery Disease in Patients Undergoing Coronary Angiography.2023Angiology
  15. Electrocardiographic changes in acute myocardial infarction with acute occlusion of all triple coronary arteries.2023Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, IncFree full text
  16. Comparison of two diagnostic strategies for patients with stable chest pain suggestive of chronic coronary syndrome: rationale and design of the double-blind, pragmatic, randomized and controlled OPERATE Trial.2023BMC cardiovascular disordersFree full text
  17. Comparison of risk assessment strategies incorporating coronary artery calcium score with estimation of pretest probability to defer cardiovascular testing in patients with stable chest pain.2023BMC cardiovascular disordersFree full text
  18. Characterization of lncRNA-associated ceRNA network to uncover novel potential biomarkers in coronary artery disease.2023MedicineFree full text
  19. Kinesiophobia and self-management behaviour related to physical activity in Chinese patients with coronary heart disease: The mediating role of self-efficacy.2023Nursing openFree full text
  20. A five-parameter score for predicting saphenous vein graft degenerative and/or occlusive disease in recurring ischemic symptoms after one year post coronary artery bypass grafting.2023Perfusion
  21. The Preventive Effect of Alprostadil on the Contrast-Induced Nephropathy of Coronary Heart Disease Treated by Percutaneous Coronary Intervention in Moderate and High-Risk Population Stratified by Mehran Score.2022AngiologyRCT
  22. Perioperative coronary artery spasm after off-pump coronary artery bypass grafting in the non-manipulated coronary artery.2022BMC cardiovascular disordersFree full text
  23. Correlation of triglyceride-glucose index and dyslipidaemia with premature coronary heart diseases and multivessel disease: a cross-sectional study in Tianjin, China.2022BMJ openFree full text
  24. Impact of persistent subclinical hypothyroidism on clinical outcomes in non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention.2022Clinical endocrinology
  25. Coronary calcification improves the estimation for clinical likelihood of obstructive coronary artery disease and avoids unnecessary testing in patients with borderline pretest probability.2022European journal of preventive cardiology
  26. Comparison of Different Investigation Strategies to Defer Cardiac Testing in Patients With Stable Chest Pain.2022JACC. Cardiovascular imaging
  27. Correlation between platelet-derived growth factor-B gene polymorphism and coronary heart disease.2022Journal of clinical laboratory analysisFree full text
  28. Validation and Comparison of PROMISE and CONFIRM Model to Predict High-Risk Coronary Artery Disease in Symptomatic and Diabetes Mellitus Patients.2022Reviews in cardiovascular medicine
  29. Comparison of NICE and ESC strategy for risk assessment in women with stable chest pain: a coronary computed tomography angiography study.2022Reviews in cardiovascular medicine
  30. Inflammatory Indicators and Hematological Indices in Contrast-Induced Nephropathy Among Patients Receiving Coronary Intervention: A Systematic Review and Meta-Analysis.2021Angiology
  31. Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention.2021BMC nephrologyFree full text
  32. Standard vs. double dose of intravenous nicorandil in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing elective coronary procedures.2021Coronary artery diseaseRCT
  33. Flow reserve fraction: the optimal choice in lesion assessing and interventional guiding for patient with unstable angina pectoris and intermediate lesion wrapped with myocardial bridge: a case report.2021Journal of cardiothoracic surgeryFree full text
  34. Clinical outcomes after percutaneous coronary intervention for early versus late and very late stent thrombosis: a systematic review and meta-analysis.2021Journal of thrombosis and thrombolysisFree full text
  35. Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction.2021Lipids in health and diseaseFree full text
  36. Bivalirudin in patients undergoing percutaneous coronary intervention and independent predictors of postoperative adverse events in these patients: A real world retrospective study.2021MedicineFree full text
All its trials on ClinicalTrials.gov, any status15
  1. TTE Improves Clinical Management of Stable Chest PainRecruitingNCT07063147Lead sponsorStart 2025-01
  2. CCTA Improves Clinical Management of Stable Chest PainRecruitingNCT04691037Lead sponsorStart 2016-01
  3. Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac DysfunctionRecruitingNCT07110415Study sitePhase 4Start 2025-11
  4. Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS SystemNot yet recruitingNCT04995159Study siteN/AStart 2021-09
  5. Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy ApparatusStatus unknownNCT05649488Study siteN/AStart 2023-02
  6. Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery DiseaseCompletedNCT05509296Study siteN/AStart 2022-09
  7. The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery StenosisStatus unknownNCT04569669Study siteN/AStart 2020-10
  8. Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent RestenosisCompletedNCT04240444Study siteN/AStart 2020-10
  9. Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)CompletedNCT04624854Study sitePhase 4Start 2020-10
  10. Quantitative Flow Ratio (QFR) Guided Coronary Artery Bypass Grafting for Patients Undergoing Primary Valve Surgery With Concomitant Coronary Artery DiseaseActive, not recruitingNCT03977129Study siteN/AStart 2019-08
  11. Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast MediumCompletedNCT03671603Study siteStart 2018-11
  12. Clinical and Genetic Characteristics of Coronary Artery Disease in Chinese Young AdultsStatus unknownNCT02496858Study siteStart 2017-05
  13. Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery DiseaseCompletedNCT01735305Study siteStart 2012-11
  14. A Trial to Evaluate Efficacy of Heart-protecting Musk PillStatus unknownNCT01897805Study sitePhase 4Start 2011-07
  15. Acarbose Cardiovascular Evaluation TrialCompletedNCT00829660Study sitePhase 4Start 2009-02

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 4 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 112025

6 hospitals in Tianjin for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025

10 hospitals in Tianjin for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Posted
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Tianjin for Fabry disease80 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    Phase
    Not given
    Started
    2025-11
    Posted
    Registry
    NCT07187440

    Age 7 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led1
  1. Vericiguat improves cardiac function and microcirculation of a male patient with Fabry disease: A case report.2024Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, IncFree full text
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseRecruitingNCT07187440Study siteStart 2025-11

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

天津市胸科医院

Tianjin Chest Hospital

天津

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
TJCH

Suggest a correctionDownload the data